AURA
Aura Biosciences, Inc.
Aura Biosciences (AURA) Q2 2026 earnings
Published Aug 11, 2026
AI summary
- GAAP EPS −$0.48 missed the −$0.38 consensus by $0.10, down from −$0.47 a year ago.
- Aura fully enrolled its Phase 3 CoMpass trial for early choroidal melanoma with 108 patients.
- The company is refocusing its strategy on ocular oncology and deprioritizing its NMIBC program.
- A 20% workforce reduction was implemented to extend the company's cash runway into the first half of 2029.
- Net loss for the second quarter was $45.6 million, compared to $27.0 million in the prior year period.
Results vs analyst consensus
Revenue
Not reported in this release.
EPS · GAAP (street basis)
Reported · Diluted EPS (GAAP, street basis)
−$0.48
Consensus −$0.38
Missed by $0.10GAAP EPS: −$0.48
Consensus: Yahoo Finance · Q2 2026 · EPS estimate at release
Revenue display rounded; difference uses exact result.
Next quarter outlook
No guidance in this release.
What to watch
- The company expects to incur restructuring charges of approximately $2.9 million to $3.2 million.
- Several key executives, including the Chief Financial and Business Officer, are stepping down.
Read original report
Source: Aura Biosciences, Inc. press release · SEC Form 8-K exhibit 99.1